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SUMMARY  Doxycycline hyclate 20 mg bid is an effective 
maintenance dosage in patients with inflammatory acne. 
Twelve subjects aged 14 to 36, both men and women, 
completed a 16-week study to demonstrate the effectiveness 
of subantimicrobial dosing of doxycycline hyclate. Seventeen 
subjects were screened, and three withdrew before receiving 
any medication. The subjects were given doxycycline hyclate 
100 mg daily for eight weeks. One subject withdrew due to 
unrelated side effects. Eleven subjects had a 50% reduction 
of lesions at eight weeks, which qualified them to enter the 
second eight-week phase of the study. This group received 
either doxycycline hyclate 20 mg bid or placebo. The six 
subjects receiving doxycycline hyclate 20 mg bid maintained 
their improvement, while the placebo group did not.  
KEY WORDS  acne vulgaris, subantimicrobial dosing of 
doxycycline, inflammatory acne
INTRODUCTION
 Antimicrobials have been the mainstay of acne 
therapy since their serendipitous introduction over 
a half-century ago (1). Initially, Marion Sulzberger 
suggested the concept of a loading dose, followed 
by maintenance therapy, to which he referred as 
“morbistatic therapy” (2). Clinicians, during the 
second half of the twentieth century, have vacil-
lated between utilizing high doses throughout the 
course of treatment and employing lower doses, 
once diminution of inflammatory signs occur.
 In recent years, doxycycline has become an in-
creasingly important agent in the acne armamen-
tarium, its efficacy having been established for 
treating this sebaceous gland disorder over three 
decades ago (3,4). The advent of the subantimi-
crobial dosage (SD doxy) concept has raised the 
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question, once again, of utilizing lower dosing, af-
ter initial improvement. To document this concept, 
we conducted the following clinical trial.
MATERIALS AND METHODS
 Seventeen patients, aged 14 to 36 years, having 
inflammatory acne of six-month duration or more, 
were screened for a prospective randomized clini-
cal trial to evaluate the role of SD doxy 20 mg bid 
(Periostat®) as maintenance therapy for inflamma-
tory acne*. To qualify, the subjects needed to have 
15 to 40 facial inflammatory lesions (papules and 
pustules) with no more than 5 acne abscesses. 
They also were required to have a minimum score 
of 2 on the Clinician’s Global Assessment Scale 
and to have no allergy to doxycycline.
 Each participant received up to eight weeks of 
doxycycline hyclate 100 mg daily. If the number of 
inflammatory lesions were reduced by 50% at the 
fourth or eighth week, the subject could enter the 
second phase of the study, which required eight 
weeks of SD doxy 20 mg bid vs. matched placebo. 
Subjects were permitted to wash with a mild soap 
(Purpose®), but no other topicals or other antimi-
crobials were permitted during the course of the 
trial.
 Once qualified, the subjects were evaluated at 
the end of 4, 8, 12, and 16 weeks, at which time 
lesion counts and global observations were made 
(5). Changes between baseline and subsequent 
visits were recorded. Photographs supplemented 
these observations. 
RESULTS
 Seventeen subjects met the criteria and en-
tered the study. Three subjects withdrew from the 
trial prior to receiving medication due to logistical 
problems. Two subjects did not improve sufficiently 
by the eighth week and were not randomized. One 
subject discontinued the trial early due to recur-
rent episodes of myoclonic twitching, a condition 
which she had developed several years before; 
this was unrelated to the study medication.  
 None of the eleven subjects achieved the 50% 
reduction in lesions until the eight-week visit, at 
which time they began the second phase of the 
trial: SD doxy 20 mg bid vs. placebo. None of the 
subjects completing the trial reported unwanted 
side effects. 
 The six subjects receiving SD doxy 20 mg 
bid were able to maintain the improvement dur-
ing the ninth to sixteenth week of the trial, while 
the placebo group forfeited much of the improve-
ment obtained during the first part of the trial 
(Figs. 1 and 2).
Figure 1. Mean changes in lesion count from 
baseline.
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DISCUSSION
 Doxycycyline has been known to be effective 
in the treatment of acne for several decades (4). 
The mechanism of action of this antibiotic, like 
other agents useful in the treatment of acne, vacil-
lates between being unknown and being unclear 
(6). Whether the role of antimicrobials is that of 
an anti-chemotactic agent (7) or a pharmaceutical 
agent that attacks Propionibacterium (P.) acnes 
(8) is one that has baffled the finest dermatologic 
minds (6). The morphology and pathology of this 
sebaceous gland disorder are clear, but the sug-
gestions of interleukins and tumor necrosis factor 
being involved remain speculative (9).  
 Added to the dilemma is the fact that antimicro-
bials produce resistant P. acnes (8) and possibly 
the overgrowth and resistant patterns of such bac-
teria as Streptococcus pyogenes (10). The tetra-
cyclines are also implicated in causing candidia-
sis, particularly vaginal candidosis. Doxycycline 
has a good safety profile; the side effects of full 
doses of doxycycline, while not common, include 
esophagitis (11), pseudotumor cerebri (12), and 
onycholysis (13).
 SD doxy 20 mg bid had previously been shown 
to be effective in treating inflammatory acne dur-
ing a six month regimen, where acne lesions were 
reduced by at least 50% with a similar reduction of 
non-inflammatory lesions (comedones). It has no 
observable effect on P. acnes, nor did other resis-
tant organisms emerge (9) due to the fact that the 
plasma concentration never reaches an antibacte-
rial level. SD doxy 20 mg bid has also been found 
to reduce inflammation for up to 18 months with no 
significant unwanted effect. In addition, the SMD 
doxycycline 20 mg bid regimen seems to eliminate 
the possibilities of photosensitivity, gastrointesti-
nal upset, and yeast production associated with 
higher dosing.
 SMD doxycycline 20 mg bid has been studied 
extensively in periodontal disease, where it has 
been demonstrated to inhibit polymorphonuclear 
leukocyte-derived collagenase (MMP-8) and  pre-
vent the development of inflammatory cytokines. 
This halts the destruction of tissue that can occur 
with inflamed periodontal tissue. SD doxy 20 mg 
bid has been postulated to stop the production of 
inflammatory cytokines that up-regulate the reac-
tions to P. acnes. These include IL-6, IL-1β, and 
TNF-α. Other possibilities may be the prevention 
of the down-regulation of P. acnes reducing the 
free fatty acids that promote neutrophil activity 
through their potent chemokine activity (9).
This trial demonstrated that SD doxy 20 mg bid 
could maintain the benefits of full dose doxycycline 
hyclate (100 mg) daily for two months. Because 
no medicated facial washes or other topical treat-
ments were used in the trial, the observed benefits 
of SD doxy 20 mg bid could be considered inde-
pendent of any other therapy. While single modal-
ity still cannot be advocated, this study also dem-
onstrated that SD doxy 20 mg bid could maintain 
the diminution of acne lesions without any adjunct 
of washes or other topicals, a concept first sug-
gested by Sulzberger fifty years ago (2).
 CONCLUSIONS
 SD doxy 20 mg bid permits the maintenance 
of improvement in patients with inflammatory acne 
for at least eight weeks, initially achieved by eight 
weeks of doxycycline 100 mg daily. No unwanted 
side effects were noted in this clinical trial.
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